How Eli Lilly Is Thinning Out the Competition
Pharmaceutical company Eli Lilly (NYSE: LLY) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro. It is too early to tell whether the drug will boost Lilly's sagging revenue, but it does have enormous potential in several huge markets. Early results suggest that the drug could help the company capture crucial share in these key segments.
On May 13, the Food and Drug Administration approved Mounjaro's weekly injection for adults with type 2 diabetes. The company's clinical trials showed that Moujaro lowered hemoglobin A1C, a measure of blood sugar control, by 1.6% more than a placebo and 0.5% more than competitor Novo Nordisk's semaglutide. Mounjaro uses a first-in-class dual action mechanism involving two hormones necessary for blood sugar control.
Effectively, this means that Mounjaro is a more advanced version of the company's current top-selling blockbuster Trulicity. Both drugs act in the GLP-1 hormone pathway, but Mounjaro's second component adds another layer of protection to stabilize blood sugar levels.
Source Fool.com
